✦ LIBER ✦

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

✍ Scribed by McCabe, Michael T.; Ott, Heidi M.; Ganji, Gopinath; Korenchuk, Susan; Thompson, Christine; Van Aller, Glenn S.; Liu, Yan; Graves, Alan P.; III, Anthony Della Pietra; Diaz, Elsie; LaFrance, Louis V.; Mellinger, Mark; Duquenne, Celine; Tian, Xinrong; Kruger, Ryan G.; McHugh, Charles F.; Brandt, Martin; Miller, William H.; Dhanak, Dashyant; Verma, Sharad K.; Tummino, Peter J.; Creasy, Caretha L.

Book ID: 119973499
Publisher: Nature Publishing Group
Year: 2012
Tongue: English
Weight: 651 KB
Volume: 492
Category: Article
ISSN: 0028-0836
DOI: 10.1038/nature11606

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Validation of the histone methyltransfer

Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker

✍ Masashi Takawa; Ken Masuda; Masaki Kunizaki; Yataro Daigo; Katsunori Takagi; Yuk 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 563 KB

Proteasome inhibition with bortezomib: A

Proteasome inhibition with bortezomib: A new therapeutic strategy for non-Hodgkin's lymphoma

✍ John P. Leonard; Richard R. Furman; Morton Coleman 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 203 KB

## Abstract The incidence of non‐Hodgkin's lymphoma (NHL) has markedly increased in the US and other westernized countries in recent years and presents a considerable clinical challenge. NHL is divided into subtypes that follow an aggressive or indolent course. Follicular lymphoma (FL), the most co

[RSC Drug Discovery] New Therapeutic Str

[RSC Drug Discovery] New Therapeutic Strategies for Type 2 Diabetes Volume 6248 || Chapter 12. Inhibition of Glycogen Phosphorylase as a Strategy for the Treatment of Type 2 Diabetes

✍ Jones, Rob M 📂 Article 📅 2012 🏛 Royal Society of Chemistry ⚖ 1010 KB

Emerging Drugs and Targets for Alzheimer

Emerging Drugs and Targets for Alzheimer's Disease Volume 1 || Chapter 10. Activating PP2A as a Therapeutic Intervention Strategy in Alzheimer's Disease

✍ Martinez, Ana 📂 Article 📅 2010 🏛 Royal Society of Chemistry ⚖ 143 KB

SLV310, a molecule combining potent dopa

SLV310, a molecule combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition, active in preclinical models for antipsychotic as well as anxiolytic activity

✍ T. Tuinstra; A.H.J. Herremans; J.A.M. Van der Heyden; A.C. McCreary; M.B. Hessel 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 131 KB

SLV310, a molecule combining potent dopa

SLV310, a molecule combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition, active in preclinical models for antipsychotic as well as anxiolytic activity

✍ T. Tuinstra; A.H.J. Herremans; J.A.M. Van der Heyden; A.C. McCreary; M.B. Hessel 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 150 KB